Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: GlobeNewswire
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme. The cash refund relates to the cost of eligible research and development activities conducted during the financial year ended 30 June 2023, and represents the amount disclosed in the company’s audited financial statements. These funds will be used to further Alterity’s Phase 2 clinical trials in MSA, ATH434-201 and ATH434-202, along with planning for a potential Phase 3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including Parkinson’s Disease, and general working capital. Ab
Show less
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewswire
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024GlobeNewswire